Previous studies have revealed that the immune system influences tumor development and clinical outcomes. NKG2DLs have an important role in cancer immunosurveillance and have clinicopathological significance.31, 32, 33, 34, 35 In BC, however, conflicting results have been reported. Some researchers implied that high expression of MICA/B resulted in a favorable outcome concerning the relapse-free period in early BC patients.35 However, higher MICA expression was found as an indicator of poor prognosis in BC.36 In addition, most previous studies were focused on the association of total MICA/B or MICA expression with clinical outcomes, whereas few considered the clinicopathological significance of MICB. In this study, we confirmed that MICA/B expression levels in BC tissues were inversely associated with TNM stage (Figures 1a–c). Importantly, we found that patients with high MICB expression showed longer overall survival than patients with low MICB expression. However, the different expression levels of MICA showed no significant influence on the survival of BC patients (Figures 1d and e). Together, these results suggest that MICB may act as a predictive factor in BC.